vaccines

Participants in the challenge commit to taking key actions to help get their campus communities vaccinated.

Researchers and volunteers in Rochester have been involved in the testing of the Pfizer/BioNTech vaccine since May. The vaccine study can trace its roots back to decades of research conducted at Rochester.

An interim analysis of study data from a coronavirus vaccine being developed by Pfizer and BioNTech indicates that the vaccine is highly effective in preventing COVID-19. Researchers and volunteers in Rochester have been involved in the testing of the vaccine since May, when the first human studies were launched, and technologies used in the development of the vaccine can trace their origins to decades of infectious disease research conducted at the University of Rochester Medical Center.

Largely unreported in 2006 was the remarkable story of three Rochester virologists whose innovation, dedication, and perseverance resulted in the key breakthrough that lies at the heart of the first vaccine targeting the leading cause of cervical cancer.

Michael Gottlieb '73M (MD), examines AIDS awareness posters that are part of the AIDS Education Posters Collection, a collection of more than 6,500 AIDS education posters from around the world. Gottlieb, a graduate of the University of Rochester School of Medicine and Dentistry, was the first to identify the disease that would come to be known as AIDS.

On Thursday, Oct. 30, University Health Service (UHS) staff will attempt to vaccinate 5,000 students, faculty and staff against this year’s flu virus. The effort will doubly serve as a test of emergency preparedness to practice delivering mass quantities of vaccine or drug in response to an urgent public health concern. All River Campus-based students, faculty and staff are asked to consider participating in this clinic if they wish to receive the flu shot this year.